Asston Pharmaceuticals
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 09 Jul 2025 – 11 Jul 2025
- Listing date
- 16 Jul 2025
- Face value
- ₹10 per share
- Issue price
- ₹123 per share
- Lot size
- 1,000 shares
- Issue type
- Book Building issue
- Total issue size
- ₹27.56 Cr
- Market cap at offer price
- ₹105 Cr
- Promoter holding
- 68.76% → 50.66% pre-issue → post-issue
- ISIN
- INE0SJX01015
- Registrar
- Maashitla Securities Pvt.Ltd.
- Lead managers
- Sobhagya Capital Options Pvt.Ltd.
- Registered office
- 4th Floor, Office No.A-431 Balaji Bhavan, Plot No 42A Sector-11 CBD Belapur, Maharashtra
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 6,35,000 | — | — |
| Market maker | 1,13,000 | — | — |
Application size
Minimum 1,000 shares per lot, in multiples, at ₹123
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 1,000 | ₹1,23,000 |
| S-HNI (min) | 2 | 2,000 | ₹2,46,000 |
| S-HNI (max) | 8 | 8,000 | ₹9,84,000 |
| B-HNI (min) | 9 | 9,000 | ₹11,07,000 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Valuation and performance
Valuation at offer price
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 6.90 | 9.32 |
| P/E (×) | 17.83 | 13.20 |
| Price to book (×) | 12.07 | — |
| Market cap | — | ₹105 Cr |
Key performance indicators
- Return on net worth
- 40.36%
- ROCE
- 51.25%
- Debt / equity
- 0.68
- PAT margin
- 17.27%
- EBITDA margin
- 24.60%
- NAV per share
- ₹17.09
- Price to book
- 12.07
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Asston Pharmaceuticals
Asston Pharmaceuticals Limited, incorporated on April 16, 2019, is a pharmaceutical company that manufactures and exports both pharmaceutical formulations and nutraceutical products in domestic and various African and Asian markets. The company manufactures tablets, capsules, oral liquids, external preparations (ointments, creams, gels, lotions), and oral powders. Beyond direct sales, the company also manufactures pharmaceutical products for different marketers on a loan license or contract manufacturing basis. From manufacturing to exports and distributions, the company takes responsibility and oversees each phase of the supply chain, working with WHO-GMP certified contract manufacturers and FDA-accredited laboratories.
Company Analysis
from DRHPAsston Pharmaceuticals Limited manufactures and exports pharmaceutical formulations and nutraceutical products across domestic and African markets.
Asston Pharmaceuticals Limited, incorporated on April 16, 2019, is a pharmaceutical company that manufactures and exports both pharmaceutical formulations and nutraceutical products in domestic and various African and Asian markets. The company manufactures tablets, capsules, oral liquids, external preparations (ointments, creams, gels, lotions), and oral powders. Beyond direct sales, the company also manufactures pharmaceutical products for different marketers on a loan license or contract manufacturing basis. From manufacturing to exports and distributions, the company takes responsibility and oversees each phase of the supply chain, working with WHO-GMP certified contract manufacturers and FDA-accredited laboratories.
Objects of the Issue
- Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit ₹600.00 lakhs p.101
- Funding the incremental working capital requirements of our Company ₹1,300.00 lakhs p.101
- Repayment and/or prepayment, in part or full, of certain of our outstanding borrowings availed by our Company ₹100.00 lakhs p.101
- General Corporate Purposes [●] p.101
Issue Structure
- Total Issue
- Up to 22,41,600 Equity Shares of face value of ₹10/- aggregating to ₹[●] Lakhs
- Fresh Issue
- Up to 22,41,600 Equity Shares of face value of ₹10/- each aggregating up to ₹[●] Lakhs
- Offer for Sale
- N.A.
- Price Band
- To be decided by the Company in consultation with the BRLM and will be advertised [●]
- Lot Size
- [●] Equity Shares and in multiples of [●] Equity Shares thereafter
- Face Value
- ₹10/- per Equity Share
Business Model
The company earns revenue through two primary channels: (1) manufacturing and marketing of pharmaceutical formulations and nutraceutical products under its own brand 'Asston' for direct sales, and (2) contract manufacturing of pharmaceutical products for various marketers on a loan license basis. Revenue is derived primarily from exports (84.19% in the period ended November 30, 2024) to African markets, with a growing domestic market segment.
Business Segments
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dr. Ashish Narayan Sakalkar | Promoter | 29.54% | [●] |
| Saili Jayaram More | Promoter | 29.54% | [●] |
| Sachin Chandrakant Badakh | Promoter | 9.98% | [●] |
Leadership
Auto-extracted from the company's DRHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official DRHP before relying on it.